Diagonal Bio AB (DIABIO) — Financial Flexibility Index
Latest as of September 2025:
-1.07x
Diagonal Bio AB (DIABIO) has a Financial Flexibility Index of -1.07x as of September 2025. Free cash flow of Skr-2.27 Million (operating CF Skr-2.27 Million minus capex Skr0.00) represents -1% of total liabilities (Skr2.13 Million).
Financial Flexibility Index
-1.07x
Free Cash Flow / Total Liabilities
Free Cash Flow
Skr-2.27 Million
Operating CF − Capex
Total Liabilities
Skr2.13 Million
SEK
Capital Expenditures
Skr0.00
SEK
Diagonal Bio AB Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for Diagonal Bio AB across 5 annual periods. See DIABIO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Diagonal Bio AB (2020–2024)
Year-by-year free cash flow to debt coverage for Diagonal Bio AB. For the full company profile including market capitalisation, see market cap of Diagonal Bio AB.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.77x | Skr-12.10 Million | Skr-13.77 Million | Skr2.54 Million | ▼ -3412.7% |
| 2023 | -0.14x | Skr-985.00K | Skr-5.23 Million | Skr7.26 Million | ▲ +96.5% |
| 2022 | -3.90x | Skr-10.82 Million | Skr-15.77 Million | Skr2.78 Million | ▼ -255.5% |
| 2021 | -1.10x | Skr-2.35 Million | Skr-10.94 Million | Skr2.14 Million | ▼ -622.0% |
| 2020 | 0.21x | Skr226.67K | Skr226.67K | Skr1.08 Million | — |
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities